8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  October 8, 2010

CHINA EXECUTIVE EDUCATION CORP.

 (Exact name of registrant as specified in its charter)

Nevada	000-54086	75-3268300
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Hangzhou MYL Business Administration Consulting Co. Ltd.

Room 307, Hualong Business Building,

110 Moganshan Road, Hangzhou, P.R.China 310005

(Address of Principal Executive Offices, including Zip Code)

Registrant's telephone number, including area code:   (86) 0571-8880-8109

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of October 8, 2010, the Board of Directors (the “Board”) of China Executive Education Corp. (the “Company”) appointed Hongmiao Chen, Tony Ho, Pokai Hsu, and Hongbo Shen to serve as directors of the Company.

Ms. Chen, age 50, currently serves as the general manager of Shanghai Da Ketang Tea Corporation.  She has held this position since May 2005.  Ms. Chen entered into an independent director’s agreement with the Company, dated October 8, 2010, pursuant to which the Company agreed to pay RMB 36,000 (approximately $5,390) in annual compensation for her services.  Ms. Chen also serves as a member of the Audit Committee of the Board.

Mr. Ho, age 36, has served as a project director and consultant for various companies including Miracle Works Media Corporation, Power Source Energy Co., Ltd., Solar Focus, Atomtech Energy & Industrials Co., Ltd., Pealinux International, Kent Periscope, Ltd., StarBio Technology Co., Ltd., Headwin Technology Co., Ltd., King Polyechnic Engineering Co., Ltd., the SYSCOM Group, EGuider Digital Technology Consulting Limted and the Corporate Synergy Development Center.  Mr. Ho also has served as the Information Officer Assistant Manager and Assistant Manager of the Information Technology Group of Taishin Bank International Bank.  Mr. Ho entered into an independent director’s agreement with the Company, dated October 8, 2010, pursuant to which the Company agreed to pay RMB 36,000 (approximately $5,390) in annual co mpensation for his services.  Mr. Ho also serves as a member of the Audit Committee of the Board.

Mr. Shen, age 30, currently serves as an Associate Professor at Fudan University.  Prior to this position, Mr. Shen was a research fellow at Tsinghua University.  Mr. Shen holds a Ph.D. in Accounting and is certified by the Association of Chartered Certified Accountants.  Mr. Shen entered into an independent director’s agreement with the Company, dated October 8, 2010, pursuant to which the Company agreed to pay RMB 60,000 (approximately $8,990) in annual compensation for his services as a director and as the Chair of the Audit Committee of the Board.

Mr. Hsu, age 38, currently serves as the Company’s Chief Operating Officer.  He has held this position since February 12, 2010.  Mr. Hsu joined Asia Magic Your Life Group in 2003.  From 2002 to 2003, Mr. Hsu served as the general manager at Beijing Hongyuan Yingtong Cultural Press Co., Ltd.  Prior to that, Mr. Hsu worked for two years as the chief consultant at Du Yunsheng Consulting Co., Ltd.  Mr. Hsu has given over 2,300 lectures in the last 8 years to audiences of over 200,000 people.  In 2006, his bestseller, How to Be No.1 in China, broke the Guinness world record on the number of book sales at a signing event.  Mr. Hsu receives compensation for his service as the Company’s Chief Operating O fficer.  However, he will not receive any additional compensation for his service as a director of the Company.

No family relationships exist between these new directors and any director or executive officer of the Company.  There is no arrangement or understanding pursuant to which these new directors were appointed as a director of the Company, and there are no related party transactions between these new directors and the Company reportable under Item 404(a) of Regulation S-K.

Item 9.01.              Financial Statements and Exhibits.

(d)           Exhibits

Exhibit 10.1 Form of Independent Director Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA EXECUTIVE EDUCATION CORP. Dated:  October 8, 2010
By	/s/ Kaien Liang
	Name: Kaien Liang Title:   Chairman and Chief Executive Officer

EXHIBIT INDEX

Form 8-K

		Filed
Exhibit No.	Description	Herewith	By Reference
10.1	Form of Independent Director Agreement.	X

EX-10.1

Exhibit 10.1

Appointment as a Non-Executive Director of China Executive Education Corp.

Date: ___________, 2010

Dear Mr. [                                ],

This letter confirms your appointment on ___________, 2010 as a Non-Executive Director of China Executive Education Corp., a Nevada corporation (the “Company”), [and as the Chair of the Audit Committee of the Company’s Board of Directors (the “Board”)] (the “Appointment”) and outlines the terms of the Appointment.

Appointment

1.Subject to your consent to act as a Director of the Company, you will hold office from ___________, 2010 until you fail to be re-elected or your earlier resignation or removal from office.

2.Notwithstanding any other provision of this letter, the Company may terminate your Appointment in accordance with relevant laws and regulations or the Company’s by-laws, or upon your resignation.  You may resign by providing to the Company’s Chairman your written notice of resignation.  Upon such termination or resignation for any reason, you shall not be entitled to any damages for loss of office and no fee will be payable to you with respect to any remaining portion of the term of the Appointment.

3.During the Appointment, you also may be asked to serve on one or more other committees of the Board.

4.Based on the information you have provided to the Company on your background and experience, the Company has determined that you qualify as an independent Non-Executive Director of the Company under the applicable standards and rules and you will be identified as such in the Company’s annual report and other documentation. If your current circumstances change and you believe that your independence may be in doubt, you agree to discuss this with the Chairman as soon as practicable.

Time Commitment

5.The Company anticipates a time commitment of no fewer than 15 days per year, but the nature of the role makes it impossible to be specific about the time commitment involved in your Appointment. You are expected to attend regular and emergency Board meetings. You also will be expected to attend meetings of any Board committee of which you are a member. In addition, you will be expected to devote appropriate preparation time in advance of each meeting. Attendance of meetings may be in person or via teleconference, if available.

6.By accepting the Appointment, you confirm that you are able to allocate sufficient time to perform your role.

Page 1 of 6

Role

7.As a Non-Executive Director, you have the same legal responsibilities to the Company as any other Director.

8.The Board as a whole is collectively responsible for promoting the success of the Company by directing and supervising the Company’s affairs. The Board:

·     provides leadership of the Company within a framework of prudent and effective controls which enable risk to be assessed and managed;

·     sets the Company’s strategic aims, ensures that the necessary financial and human resources are in place for the Company to meet its objectives, and reviews management performance; and

·      sets the Company’s values and standards and ensures that its obligations to its shareholders and others are understood and met.

9.In addition to these requirements of all Directors, the role of the Non-Executive Director has the following key elements:

·      Strategy: Non-Executive Directors should constructively challenge and contribute to the development of strategy;

·      Performance: Non-Executive Directors should scrutinize the performance of management in meeting agreed goals and objectives and monitor the reporting of performance;

·      Risk: Non-Executive Directors should satisfy themselves that financial information is accurate and that financial controls and systems of risk management are robust and defensible; and

·      People: Non-Executive Directors are responsible for determining the appropriate levels of remuneration for the Company’s executive officers and have a prime role in appointing, and where necessary removing, senior management and in succession planning.

10.In addition, responsibilities of the Audit Committee as a whole shall include the following:

·      Pre-approve audit and non-audit services;

·      Receive reports from auditor on critical accounting policies; receive reports from auditor on discussion with management on alternative GAAP, their effects, and the auditor’s preference; receive reports from auditor on material communications with management. Auditor reports shall be delivered directly to the Audit Committee.

·      Oversee the auditor engagement, including engaging, compensation, and resolving disagreement with management on financial reporting.

·     Provide procedures to receive, retain, and treat complaints; provide procedures to confidentially handle employee complaints.

Page 2 of 6

Compensation

11.As a Non-Executive Director, you will be paid a base fee currently of RMB [] per annum. [In addition, you will be paid a fee of RMB [] per annum for acting as Chair of the Audit Committee.] Fees are payable quarterly in arrears, in either RMB or equivalent USD, and will be deposited into your bank account, details of which you will provide to the Company.  You will not be paid any bonus or other compensation for your service as a Director.

12.In the event that you cease to act as a Director [and/or Chair of Audit Committee] of the Company due to termination or resignation for any reason or failure to be re-elected, you will only receive compensation for the period in which you served as a Director.

Expenses

13.In addition to the compensation described in 11 above, the Company will reimburse you for all reasonable and properly documented expenses you incur in performing your role, including but not limited to traveling, lodging, and reasonable meal expenses in the trips. You should submit any details of expenses incurred to the Company’s Secretary. The Company shall pay the reimbursed amount in cash or to your designated account no later than five (5) working days after receiving the reimbursement documents.

Indemnity and D&O Liability Insurance Coverage

14.The Company will provide and maintain directors' and officers' (D&O) liability insurance coverage for you in respect of the period for which you are a director of the Company at such levels, for such risks and subject to such terms, and for such a period after you cease to be a director of the Company, as the Company provides and maintains such coverage for its directors generally for each year thereafter, including such self insurance coverage as the Company makes available or obtains on behalf of itself or its directors.

Confidential Information

15.You agree that both during and after your time as a director of the Company, you will not use for your own or another's benefit or disclose or permit the disclosure of any confidential information about the Company, its suppliers, customers or other constituents, other than as appropriate in connection with the proper performance of your duties as a director or otherwise in accordance with prior authorization provided by the Company. Confidential information shall include, without limitation, all and any information, whether or not recorded, of the Company which you have obtained by virtue of your Appointment and which (i) the Company regards as confidential, (ii) is apparently confidential by reason of its nature or the circumst ances in which it comes to your knowledge, and/or (iii) in respect of which the Company is bound by any obligation of confidence to a third party. Confidential information may include, without limitation:

15.1all and any information relating to results of operations, financial condition, plans and prospects, business methods, corporate plans, future business strategy, management systems, borrowing activities, possible transactions with other parties, possible restructuring, liquidity issues, litigation (pending or threatened), senior management changes, securities offerings, dividend policy, and maturing new business opportunities;

Page 3 of 6

15.2all and any information relating to research and/or development projects;

15.3all and any information concerning the curriculum vitae, compensation details, work-related experience and other personal information concerning those employed or engaged by the Company;

15.4all and any information relating to marketing or sales of any past, present or future product or service of the Company including sales targets and statistics, market share and pricing statistics, marketing surveys and strategies, marketing research reports, sales techniques, price lists, mark-ups, discounts, rebates, tenders, advertising and promotional material, credit and payment policies and procedures, and lists and details of customers, prospective customers, suppliers, prospective suppliers, joint venture partners and prospective joint venture partners, including their identities, business requirements and contractual negotiations and arrangements with the Company;

15.5all and any trade secrets, secret formulae, processes, inventions, design, know-how, research projects, technical specifications and other technical information in relation to the creation, production or supply of any past, present or future product or service of the Company, including all and any information relating to the working of any product, process, invention, improvement or development carried on or used by the Company and information concerning the intellectual property portfolio and strategy of the Company; and

15.6any other information that a reasonable investor would consider important in making a decision to buy, hold or sell the Company’s securities.

16.The restrictions contained in the clause 15 above shall cease to apply to any confidential information which:

16.1may (other than by reason of your breach of these terms) become available to the public generally; or

16.2is required to disclose by law, governmental rule or regulation (in which event you shall promptly notify the Company a reasonable period in advance of such disclosure).

Other Directorships and Business Interests

17.The Company acknowledges that you have business interests other than those of the Company and that you have declared any conflicts that are apparent at present. In the event that you become aware of any potential conflicts of interest, these should be disclosed to the Chairman and Company’s Secretary as soon as they become apparent.

Page 4 of 6

Miscellaneous

18.Nothing in this letter shall create the relationship of employee and employer between you and the Company.

19.The agreement constituted by this appointment letter shall be governed by and construed in accordance with laws of the State of New York.

20.Both you and the Company irrevocably agree that the Courts of the State of New York shall have exclusive jurisdiction in relation to any claim, dispute or difference concerning this appointment letter and any matter arising therefrom.

21.Both you and the Company irrevocably waive any right that you or the Company may have to object to an action being brought in those Courts, to claim that the action has been brought in an inconvenient forum, or to claim that those Courts do not have jurisdiction.

Entire Agreement and Severability

22.This appointment letter represents the entire understanding, and constitutes the whole agreement, in relation to your appointment and supersedes any previous agreement between yourself and the Company with respect thereto and, without prejudice to the generality of the foregoing, excludes any warranty, condition or other undertaking implied at law or by custom.

23.You confirm that:

23.1in entering into the agreement constituted by this appointment letter you have not relied on any representation, warranty, assurance, covenant, indemnity, undertaking or commitment which is not contained in this appointment letter; and

23.2in any event, without prejudice to any liability for fraudulent misrepresentation or fraudulent misstatement, the only rights or remedies in relation to any representation, warranty, assurance, covenant, indemnity, undertaking or commitment given or action taken in connection with this appointment are under this appointment letter and, for the avoidance of doubt and without limitation, neither party has any right or remedy (whether by way of a claim for contribution or otherwise) in tort (including negligence) or for misrepresentation (whether negligent or otherwise, and whether made prior to, and/or in, this appointment letter).

23.3in the event that any part (including any sub clause or part thereof) of this appointment letter shall be void or unenforceable by reason of any applicable law, it shall be deleted and the remaining parts of this appointment letter shall continue in full force and effect and, if necessary, both parties shall use their best endeavors to agree any amendments to the appointment letter necessary to give effect to the spirit of this appointment letter.

Page 5 of 6

Language and Counterparts

24.This appointment letter is written in English language. In case there are any discrepancies between the original English version and its Chinese translation, the English version shall apply.

25.This appointment letter may be executed by facsimile and in counterparts, all of which taken together shall constitute one and the same instrument.

Waiver

26.The failure of either party to insist upon strict performance of any of the terms in this appointment letter shall not constitute a waiver of any of its rights hereunder. Further, the waiver by either party of the breach of any provision of this appointment letter shall not operate or be construed as a waiver of any subsequent breach thereof.

Assignment

27.The rights and benefits of the Company under this appointment letter shall be transferable and shall inure to the benefit of its successors and assigns. Your duties and obligations under this appointment letter are personal and therefore you may not assign any right or duty under this appointment letter without the prior written consent of the Company.

Yours sincerely,

________________________ 

Kaien Liang, Chairman and Chief Executive Officer

for and on behalf of China Executive Education Corp.

I, [                      ], hereby accept the terms of appointment set out in this letter.

________________________ 

Signature

________________________, 2010

Date

Page 6 of 6